Reclassification of devices: lessons from joint implants case
This article was originally published in Clinica
Executive Summary
The EU needs a proper procedure for dealing with the reclassification of medical devices. That is the opinion of Steve Owen, head of European and regulatory affairs at the UK's Medicines and Healthcare products Regulatory Agency (MHRA). It comes in the light of experience over the handling, or as some would argue, mishandling, of the reclassification of hip, knee and shoulder implants from class II to class III to include a review of the design dossier.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.